T

Theravance Biopharma
D

TBPH

9.46000
USD
-0.15
(-1.56%)
Market Closed
Volume
6,430
EPS
1
Div Yield
-
P/E
-9
Market Cap
465,188,840
Related Instruments
    A
    ACOR
    -0.26810
    (-30.48%)
    0.61160 USD
    A
    ALKS
    -0.150
    (-0.53%)
    28.200 USD
    C
    CRBP
    -0.950
    (-5.41%)
    16.610 USD
    F
    FOLD
    -0.42300
    (-4.19%)
    9.68000 USD
    G
    GLPG
    -1.130
    (-4.05%)
    26.780 USD
    I
    INSM
    -4.950
    (-6.95%)
    66.310 USD
    P
    PTCT
    -3.110
    (-7.34%)
    39.270 USD
    S
    SAGE
    -0.26000
    (-4.84%)
    5.11000 USD
    S
    SRPT
    -4.470
    (-4.10%)
    104.600 USD
    More
News

Title: Theravance Biopharma

Sector: Healthcare
Industry: Biotechnology
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).